Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
Conditions
Keywords
Vosaroxin
Brief summary
The main part of this trial is a phase II study of vosaroxin with azacitidine in older patients with newly diagnosed AML and intermediate or adverse genetic risk or MDS-EB-2. An initial safety run-in phase of the study will be performed administering the study drug vosaroxin with azacitidine in up to 18 patients. After completion of the run-in phase, toxicity and response data will be provided to the external Data and Safety Monitoring Board (DSMB) and the Trial Committee by the Coordinating Investigator. The Trial Committee will decide on the basis of these data and the recommendation of the DSMB on dose modification and the vosaroxin dose for the phase II part of the study, which will include 150 patients in total.
Interventions
DRUGVosaroxin
Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
DRUGAzacitidine
Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression.
Sponsors
Sunesis Pharmaceuticals
University of Ulm
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) 2. Patients ≥60 years of age 3. No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis for up to 10 days during the diagnostic screening phase; patients may have received prior therapy for myelodysplastic syndrome different from hypomethylating agents 4. ECOG performance status ≤2 5. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 3 month after the last dose of vosaroxin) 6. Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months). 7. Female patients of reproductive age must agree to avoid getting pregnant while on therapy and for 3 months after the last dose of vosaroxin. 8. Women of child-bearing potential including the female partners of the male patients must either commit to continued abstinence from heterosexual intercourse or apply two acceptable methods of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control. 9. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for three months after the last dose of chemotherapy) 10. Willing to adhere to protocol specific requirements 11. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out
Exclusion criteria
1. Known or suspected hypersensitivity to the study drugs and/or any excipients 2. Favorable genetics: t(15;17)(q22;q12), PML-RARA; t(8;21)(q22;q22), RUNX1-RUNX1T1; inv(16)(p13.1q22)/t(16;16)(p13.1;q22), CBFB-MYH11; mutated NPM1 without FLT3-ITD or with FLT3-ITDlow 3. Prior treatment for AML except hydroxyurea 4. Prior treatment for MDS with hypomethylating agents 5. ECOG performance status \>2 6. Patients who are not eligible for intensive chemotherapy 7. Inadequate cardiac, hepatic and/or renal function at the Screening Visit defined as: * Ejection fraction \<40% confirmed by echocardiography * Creatinine \>1.5x upper normal serum level * Total bilirubin, AST or ALT \>1.5 upper normal serum level 8. Active central nervous system involvement 9. Any clinically significant, advanced or unstable disease or history of that may interfere with primary or secondary variable evaluations or put the patient at special risk, such as: * Myocardial infarction, unstable angina within 3 months before screening * Heart failure NYHA III/IV * Severe obstructive or restrictive ventilation disorder * Uncontrolled infection 10. Severe neurological or psychiatric disorder interfering with ability of giving an informed consent 11. Currently receiving a therapy not permitted during the study, as defined in Section 10.5.4 12. Patients with a currently active second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year. 13. Known history of positive test for Hepatitis B surface Antigen (HBsAg) or hepatitis C antibody or history of positive test for Human Immunodeficiency Virus (HIV) 14. Hematological disorder independent of leukemia 15. No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation 16. No consent for biobanking 17. Current participation in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the study 18. Patients known or suspected of not being able to comply with this trial protocol 19. Patients of childbearing potential not willing to use adequate contraception during study and 3 months after last dose of therapy 20. Breast feeding women or women with a positive pregnancy test at Screening visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of complete remission (CR) and CR with incomplete blood count recovery (CRi) | 2 months | Efficacy assessments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CR and rate of combined CR/CRi and CR with negativity for minimal residual disease (CRMRD-) | 2 months | Efficacy assessments |
| Duration of response (DOR) | 4 years | Efficacy assessments |
| Event-free survival (EFS) | 4 years | Efficacy assessments |
| CR and CRi in a pre-defined subgroup analysis in patients with complex karyotype | 2 months | Efficacy assessments |
| 30-day and 60-day mortality | 30 and 60 days | Safety assessments |
| Incidence and intensity of adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version v4.0 | 12 months | Safety assessments |
| Assessment of Quality of life by the EORTC Quality of Life Core Questionnaire (QLQ-C30) | 4 years | Quality of life |
| Overall survival (OS) | 4 years | Efficacy assessments |
Countries
Germany
Outcome results
None listed